Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.
To investigate the vaccine potential of both the Toxoplasma GRA2 and GRA6 antigens, the full length recombinant proteins were produced in Escherichia coli, formulated in MPL adjuvant, and used alone and in combination ("mix"), to immunize CBA/J mice. Although high ratios of specific IgG2a/IgG1 were measured against both proteins, only spleen cells from GRA2-immunized mice and mix-immunized mice produced high amounts of both IFN-gamma and IL-2 upon induction with Toxoplasma gondii Excretory-Secretory Antigens. Intra peritoneal challenge with Toxoplasma cysts resulted in significant reduction of brain cysts in GRA2- and in mix-vaccinated mice only. This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response.
Golkar
Majid
M
CNRS UMR 5163 - Université Joseph Fourier, UFR de Biologie, Institut Jean Roget, Campus Santé, Domaine de la Merci. BP 170, 38042 Grenoble cedex 09, France.
Shokrgozar
Mohammad-Ali
MA
Rafati
Sima
S
Musset
Karine
K
Assmar
Mehdi
M
Sadaie
Reza
R
Cesbron-Delauw
Marie-France
MF
Mercier
Corinne
C
D000276:Adjuvants, Immunologic; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D001921:Brain / Q000469:parasitology; D016207:Cytokines / Q000276:immunology; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D008050:Lipid A / Q000031:analogs & derivatives* / Q000276:immunology; D051379:Mice; D008808:Mice, Inbred CBA; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D016052:Protozoan Vaccines / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D014122:Toxoplasma / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000276:immunology / Q000517:prevention & control*; D022223:Vaccines, Subunit / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; C095047:GRA6 protein, Toxoplasma gondii; C106990:Gra2 protein, Toxoplasma gondii; D008050:Lipid A; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C048436:monophosphoryl lipid A